Cargando…

Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin

Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gezelius, E., Flou Kristensen, A., Bendahl, P. O., Hisada, Y., Risom Kristensen, S., Ek, L., Bergman, B., Wallberg, M., Falkmer, U., Mackman, N., Pedersen, S., Belting, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226210/ https://www.ncbi.nlm.nih.gov/pubmed/30412630 http://dx.doi.org/10.1371/journal.pone.0207387

Ejemplares similares

Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial
por: Ek, L, et al.
Publicado: (2018)

Longitudinal Assessment of Circulating Tumor Cells and Outcome in Small Cell Lung Cancer: A Sub-Study of RASTEN—A Randomized Trial with Low Molecular Weight Heparin
por: Bendahl, Pär-Ola, et al.
Publicado: (2023)

Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
por: Gezelius, Emelie, et al.
Publicado: (2022)

Increased activity of procoagulant factors in patients with small cell lung cancer
por: Pedersen, Shona, et al.
Publicado: (2021)

Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation
por: Nielsen, Thøger, et al.
Publicado: (2018)

Epidemiology of Venous Thromboembolism After Second Cancer
por: Gade, Inger Lise, et al.
Publicado: (2020)

The interrelationship between pregnancy, venous thromboembolism, and thyroid disease: a hypothesis-generating review
por: Andersen, Stine Linding, et al.
Publicado: (2021)

Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
por: Kristensen, Søren Risom, et al.
Publicado: (2022)

Validation of Postsurgical Venous Thromboembolism Diagnoses of Patients Undergoing Lower Limb Orthopedic Surgery in the Danish National Patient Registry
por: Galsklint, Josephine, et al.
Publicado: (2022)

Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer
por: Hisada, Yohei, et al.
Publicado: (2021)

Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia
por: Hisada, Yohei, et al.
Publicado: (2023)

Tissue factor–positive extracellular vesicles in plasma are not associated with venous thromboembolism in patients with ovarian cancer
por: Hisada, Yohei, et al.
Publicado: (2023)

Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
por: Lichota, Anna, et al.
Publicado: (2020)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Identifying metabolic alterations in newly diagnosed small cell lung cancer patients
por: Pedersen, Shona, et al.
Publicado: (2021)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism
por: Smythe, Maureen A., et al.
Publicado: (2016)

Circulating microvesicles and exosomes in small cell lung cancer by quantitative proteomics
por: Pedersen, Shona, et al.
Publicado: (2022)

Tissue factor and its procoagulant activity on cancer‐associated thromboembolism in pancreatic cancer: Comment by Mackman et al.
por: Mackman, Nigel, et al.
Publicado: (2022)

Shotgun-based proteomics of extracellular vesicles in Alzheimer’s disease reveals biomarkers involved in immunological and coagulation pathways
por: Nielsen, Jonas Ellegaard, et al.
Publicado: (2021)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Reply to a letter from Jackson J et al: Effect of pH on thrombin activity measured by calibrated automated thrombinography
por: Kristensen, Søren Risom, et al.
Publicado: (2020)

The effect of pH on thrombin generation–An unrecognized potential source of variation
por: Kristensen, Søren Risom, et al.
Publicado: (2020)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019
por: Thondapu, Vikas, et al.
Publicado: (2021)

Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty
por: Baker, Kevin, et al.
Publicado: (2017)

Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia
por: Hisada, Yohei, et al.
Publicado: (2023)

Heparin beyond anti-coagulation
por: Chen, Daohong
Publicado: (2021)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Venous thromboembolism after lower extremity orthopedic surgery: A population‐based nationwide cohort study
por: Gade, Inger Lise, et al.
Publicado: (2020)

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism
por: Adediran, Samuel, et al.
Publicado: (2017)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Associations between coagulation factor XII, coagulation factor XI, and stability of venous thromboembolism: A case-control study
por: Meng, Yan, et al.
Publicado: (2022)

A sensitive tissue factor activity assay determined by an optimized thrombin generation method
por: Kristensen, Søren Risom, et al.
Publicado: (2023)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer
por: Rosell, Axel, et al.
Publicado: (2021)

A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism
por: Rosell, Axel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3q0eanh4f7i5drb8ju8fhuo1ir